Soleno Therapeutics (SLNO) Cantor Global Healthcare Conference 2025 summary

Company overview and recent developments

• Focused on rare diseases, recently launched a drug for Prader-Willi syndrome (PWS) in the U.S. and filed in Europe.

• 646 patient start forms and 295 prescribers reported in Q2, indicating broad provider engagement.

• Majority of patients on therapy are under 26 years old, aligning with claims data and healthcare access trends.

• European opportunity is significant, with structured care in countries like France and Germany and similar patient numbers to the U.S.

• Financial position is strong following a recent capital raise, supporting aggressive expansion in Europe.

Patient experience and clinical benefits

• Drug addresses hyperphagia, leading to reduced food-seeking behaviors and improved daily functioning.

• Long-term benefits include better school performance, employment, and household participation.

• Real-world benefits are often measured through physician attestation and family anecdotes.

• Maximal therapeutic effects may take six to nine months, with policies typically allowing six to twelve months for assessment.

• Responders are generally identified by overall improvement rather than formal scoring systems.

Safety, monitoring, and physician support

• Side effects such as hyperglycemia and peripheral edema are consistent with clinical trial data.

• Commercial patients may have more comorbidities and less frequent monitoring than trial participants.

• Most significant side effects appear within the first few months; ongoing monitoring is emphasized.

• Physician education and support are provided through marketing materials, speakers' bureaus, and specialty pharmacy touchpoints.

• Risk-reward profile is favorable when patients are appropriately selected and monitored.